1. Home
  2. KURA vs RYI Comparison

KURA vs RYI Comparison

Compare KURA & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • RYI
  • Stock Information
  • Founded
  • KURA 2014
  • RYI 1842
  • Country
  • KURA United States
  • RYI United States
  • Employees
  • KURA N/A
  • RYI N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • RYI Metal Fabrications
  • Sector
  • KURA Health Care
  • RYI Industrials
  • Exchange
  • KURA Nasdaq
  • RYI Nasdaq
  • Market Cap
  • KURA 793.2M
  • RYI 661.1M
  • IPO Year
  • KURA N/A
  • RYI N/A
  • Fundamental
  • Price
  • KURA $7.26
  • RYI $20.75
  • Analyst Decision
  • KURA Strong Buy
  • RYI Hold
  • Analyst Count
  • KURA 11
  • RYI 1
  • Target Price
  • KURA $27.89
  • RYI $28.00
  • AVG Volume (30 Days)
  • KURA 1.7M
  • RYI 270.1K
  • Earning Date
  • KURA 02-25-2025
  • RYI 02-19-2025
  • Dividend Yield
  • KURA N/A
  • RYI 3.62%
  • EPS Growth
  • KURA N/A
  • RYI N/A
  • EPS
  • KURA N/A
  • RYI 0.64
  • Revenue
  • KURA N/A
  • RYI $4,703,700,000.00
  • Revenue This Year
  • KURA N/A
  • RYI N/A
  • Revenue Next Year
  • KURA $233.30
  • RYI $1.76
  • P/E Ratio
  • KURA N/A
  • RYI $32.60
  • Revenue Growth
  • KURA N/A
  • RYI N/A
  • 52 Week Low
  • KURA $6.98
  • RYI $17.18
  • 52 Week High
  • KURA $24.17
  • RYI $36.15
  • Technical
  • Relative Strength Index (RSI)
  • KURA 19.21
  • RYI 54.59
  • Support Level
  • KURA $7.02
  • RYI $17.18
  • Resistance Level
  • KURA $7.66
  • RYI $18.73
  • Average True Range (ATR)
  • KURA 0.34
  • RYI 0.75
  • MACD
  • KURA 0.07
  • RYI 0.47
  • Stochastic Oscillator
  • KURA 13.76
  • RYI 89.92

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority is from the United States.

Share on Social Networks: